leisure time -WSS

leisure time

author：entertainment 2025-10-04 07:30:14 - browse：8145

Verve Therapeutics CEO Sekar Kathiresan Verve

SAN FRANCISCO — The promise of genome editing has given rise to potentially curative medicines for rare, life-threatening diseases that generally affect small numbers of patients. But since Verve Therapeutics was founded in 2018, it’s had a wider aperture: using the molecular tools of genome editing to go after the most common cause of death in the world.

The plan, according to Verve CEO Sekar Kathiresan, is to edit out heart attacks for the millions of people at risk for severe cardiovascular disease. It’s a goal that’s more than a little audacious. There’s just one approved genome editing medicine, a treatment for sickle cell disease, and it only passed Food and Drug Administration review last month. Base editing, the CRISPR successor Verve uses to conduct its molecular surgery, is only a few years old.

“When we started, there were so many things that we were kind of going against the grain on,” Kathiresan told STAT at the J.P. Morgan Healthcare Conference in San Francisco this week. “In 2018, it was all about platforms, not about specific diseases and products, or taking this kind of idea for a large indication as opposed to cancer or rare disease. But we’ve always been motivated by a deep conviction in one simple research insight, which is that if your blood cholesterol is really low, lifelong, it is very hard to get a heart attack.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Marc Tessier

hotspot

WSS

Drinking less cuts risk of oral cavity, esophageal cancer: Report

SNAP should offer more nutrition education

Carvykti CAR

Prime Medicine, Myeloid Therapeutics clash over genome

'The boss' wants server deleted: New allegations emerge in Trump indictment

SEC charges former device maker CEO with $41 million fraud

explore

leisure time

leisure time

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Editas, Vertex strike deal on CRISPR

Bright Health sells Medicare Advantage business to Molina

Three trends to watch in biotech in 2024

Dobbs anniversary: the lost opportunity of abortion as health care

Timeline: Special counsel's probe into Trump's handling of classified documents

Alkermes shareholders re

Editas, Vertex strike deal on CRISPR

Virginia high school admissions case could be legal follow

Alexander Hamilton and the argument for universal insurance

focus

HCA sued by state AG for quality issues at Mission Health

The mammogram wars are not over

Bryan Kohberger seeks indictment dismissal in Idaho college killings case

Editas, Vertex strike deal on CRISPR

Will biotech layoffs continue through 2023?

Timeline: Special counsel's probe into Trump's handling of classified documents

entertainment

hotspot

knowledge

explore